Concepedia

Publication | Open Access

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

DOIFull Paper Access

81

Citations

29

References

2015

Year

Julio Rosenstock, Nikolaus Marx, Dietmar Neubacher, Thomas Seck, Sanjay Patel, Hans‐Juergen Woerle, Odd Erik Johansen
Cardiovascular Diabetology

Abstract

Linagliptin is not associated with increased CV risk versus pooled active comparators or placebo in patients with T2DM.

References

YearCitations

Page 1